Dark Forest Capital Management LP Increases Holdings in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)

Dark Forest Capital Management LP lifted its position in shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) by 16.5% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 60,386 shares of the biotechnology company’s stock after acquiring an additional 8,557 shares during the quarter. Dark Forest Capital Management LP’s holdings in Ironwood Pharmaceuticals were worth $394,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. CWM LLC raised its position in shares of Ironwood Pharmaceuticals by 55.1% during the 2nd quarter. CWM LLC now owns 6,600 shares of the biotechnology company’s stock worth $43,000 after purchasing an additional 2,345 shares during the last quarter. PNC Financial Services Group Inc. raised its position in shares of Ironwood Pharmaceuticals by 152.2% during the 4th quarter. PNC Financial Services Group Inc. now owns 4,383 shares of the biotechnology company’s stock worth $50,000 after purchasing an additional 2,645 shares during the last quarter. GAMMA Investing LLC raised its position in shares of Ironwood Pharmaceuticals by 344.1% during the 2nd quarter. GAMMA Investing LLC now owns 10,526 shares of the biotechnology company’s stock worth $69,000 after purchasing an additional 8,156 shares during the last quarter. First Dallas Securities Inc. acquired a new position in shares of Ironwood Pharmaceuticals during the 2nd quarter worth approximately $73,000. Finally, SG Americas Securities LLC acquired a new position in Ironwood Pharmaceuticals in the 1st quarter valued at $91,000.

Ironwood Pharmaceuticals Stock Down 1.0 %

IRWD stock opened at $4.02 on Friday. The company has a market cap of $629.25 million, a price-to-earnings ratio of -0.59 and a beta of 0.49. The business has a fifty day simple moving average of $5.07 and a 200-day simple moving average of $6.46. Ironwood Pharmaceuticals, Inc. has a 52 week low of $3.79 and a 52 week high of $15.70.

Insider Transactions at Ironwood Pharmaceuticals

In related news, insider Minardo John sold 9,910 shares of the company’s stock in a transaction on Monday, August 12th. The shares were sold at an average price of $4.27, for a total transaction of $42,315.70. Following the completion of the sale, the insider now directly owns 284,661 shares of the company’s stock, valued at approximately $1,215,502.47. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 12.90% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the company. Leerink Partners assumed coverage on Ironwood Pharmaceuticals in a report on Monday, September 9th. They issued a “market perform” rating and a $5.00 price target for the company. Wells Fargo & Company cut their price target on Ironwood Pharmaceuticals from $14.00 to $12.00 and set an “overweight” rating for the company in a report on Friday, August 9th. Craig Hallum cut their price target on Ironwood Pharmaceuticals from $14.00 to $10.00 and set a “buy” rating for the company in a report on Friday, August 9th. Leerink Partnrs upgraded Ironwood Pharmaceuticals to a “hold” rating in a report on Monday, September 9th. Finally, StockNews.com upgraded Ironwood Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday, July 16th. Three research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $12.17.

Ironwood Pharmaceuticals Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.